Skip to main content

ACROMICS: medicina de precisión de futuro en el diagnóstico y tratamiento de la Acromegalia

PMP22/00021

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Afrontar las Prioridades de Nuestro Entorno
Call Proyectos de Investigación de Medicina Personalizada de Precisión
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Execution centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

New molecular tools for precision medicine in pituitary neuroendocrine tumors

  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Valassi, Elena|||0000-0002-3864-0105
  • Pons, Laura|||0000-0003-0784-4110
  • Carrato, Cristina|||0000-0002-1953-8287
  • Jordà, Mireia|||0000-0003-3709-1850
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Precision, personalized, or individualized medicine in pituitary neuroendocrine tumors (PitNETs) has become a major topic in the last few years. It is based on the use of biomarkers that predictively segregate patients and give answers to clinically relevant questions that help us in the individualization of their management. It allows us to make early diagnosis, predict response to medical treatments, predict surgical outcomes and investigate new targets for therapeutic molecules. So far, substantial progress has been made in this field, although there are still not enough precise tools that can be implemented in clinical practice. One of the main reasons is the excess overlap among clustered patients, with an error probability that is not currently acceptable for clinical practice. This overlap is due to the high heterogeneity of PitNETs, which is too complex to be overcome by the classical biomarker investigation approach. A systems biology approach based on artificial intelligence techniques seems to be able to give answers to each patient individually by building mathematical models through the interaction of multiple factors, including those of omics sciences. Integrated studies of different molecular omics techniques, as well as radiomics and clinical data are necessary to understand the whole system and to finally achieve the key to obtain precise biomarkers and implement personalized medicine. In this review we have focused on describing the current advances in the area of PitNETs based on the omics sciences, that are clearly going to be the new tool for precision medicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Predictors of biochemical response to somatostatin receptor ligands in acromegaly

  • Marazuela, Mónica|||0000-0003-1158-9618
  • Martínez-Hernández, Rebeca
  • Marques-Pamies, Manuel
  • Biagetti, Betina|||0000-0002-8837-4343
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Although predictors of response to first-generation somatostatin receptor ligands (fg-SRLs), and to a lesser extent to pasireotide, have been studied in acromegaly for many years, their use is still not recommended in clinical guidelines. Is there insufficient evidence to use them? Numerous biomarkers including various clinical, functional, radiological and molecular markers have been identified. The first ones are applicable pre-surgery, while the molecular predictors are utilized for patients not cured after surgery. In this regard, factors predicting a good response to fg-SRLs are specifically: low basal GH, a low GH nadir in the acute octreotide test, T2 MRI hypointensity, a densely granulated pattern, high immunohistochemistry staining for somatostatin receptor 2 (SSTR2), and E-cadherin. However, there is still a lack of consensus regarding which of these biomarkers is more useful or how to integrate them into clinical practice. With classical statistical methods, it is complex to define reliable and generalizable cut-off values for a single biomarker. The potential solution to the limitations of traditional methods involves combining systems biology with artificial intelligence, which is currently providing answers to such long-standing questions that may eventually be finally included into the clinical guidelines and make personalized medicine a reality. The aim of this review is to describe the current knowledge of the main fg-SRLs and pasireotide response predictors, discuss their current usefulness, and point to future directions in the research of this field.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly

  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Jordà, Mireia|||0000-0003-3709-1850
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Background and Aims: Predictors of first-generation somatostatin receptor ligands (fgSRLs) response in acromegaly have been studied for over 30 years, but they are still not recommended in clinical guidelines. Is there not enough evidence to support their use? This systematic review aims to describe the current knowledge of the main predictors of fgSRLs response and discuss their current usefulness, as well as future research directions. Methods: A systematic search was performed in the Scopus and PubMed databases for functional, imaging, and molecular predictive factors. Results: A total of 282 articles were detected, of which 64 were included. Most of them are retrospective studies performed between 1990 and 2023 focused on the predictive response to fgSRLs in acromegaly. The usefulness of the predictive factors is confirmed, with good response identified by the most replicated factors, specifically low GH nadir in the acute octreotide test, T2 MRI hypointensity, high Somatostatin receptor 2 (SSTR2) and E-cadherin expression, and a densely granulated pattern. Even if these biomarkers are interrelated, the association is quite heterogeneous. With classical statistical methods, it is complex to define reliable and generalizable cut-off values worth recommending in clinical guidelines. Machine-learning models involving omics are a promising approach to achieve the highest accuracy values to date. Conclusions: This survey confirms a sufficiently robust level of evidence to apply knowledge of predictive factors for greater efficiency in the treatment decision process. The irruption of artificial intelligence in this field is providing definitive answers to such long-standing questions that may change clinical guidelines and make personalized medicine a reality.